Video

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Aditya Bardia, MD, MPH, attending physician, medical oncology, Massachusetts General Hospital; associate professor, medicine, Harvard Medical School, discusses the use of elacestrant in patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

The phase 3 EMERALD trial (NCT03778931) investigated elacestrant, a novel endocrine agent, vs standard-of-care endocrine therapy in the ER-positive, HER2-negative population. EMERALD aimed to identify an endocrine-sensitive disease subgroup that would benefit from elacestrant vs standard endocrine therapy, Bardia says. EMERALD used prior use of CDK4/6 inhibitors as a surrogate marker for endocrine-sensitive disease and found that a longer duration of prior CDK4/6 inhibition was associated with a prolonged median progression-free survival (PFS) benefit from elacestrant, as well as a PFS benefit at 6, 12, and 18 months, Bardia explains.

For example, patients with ESR1-mutant tumors who had received prior CDK4/6 inhibition for at least 12 months experienced a median PFS of 8.61 months with elacestrant vs 1.91 months with standard endocrine therapy, Bardia emphasizes. These data indicate that prior duration of CDK4/6 inhibition is predictive of endocrine-sensitive disease, and that elacestrant provides a PFS benefit for these patients, Bardia concludes.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS